Quickborn, Germany and Eindhoven, Netherlands – September 24, 2025 – Mammotome, a globally recognized leader in breast care, and Sirius Medical, a pioneer of Surgical Marker Navigation, are proud to announce an exclusive distribution agreement for the Pintuition® System in Italy and Poland. Building on the successful collaboration in the United States and Germany initiated earlier this year, Mammotome and Sirius Medical are further strengthening their partnership through this expanded commitment.
Breast cancer continues to pose a major global health challenge, underscoring the critical need for advanced technologies that enhance patient outcomes and optimize surgical procedures. The Sirius Pintuition System marks a notable innovation in breast cancer surgery, empowering surgeons with greater precision and efficiency by replacing conventional localization techniques with Surgical Marker Navigation for accurate tumor removal.
“The success we have achieved together in Germany and the United States demonstrates the strength of our partnership,” said Jan Willem Beijer, Chief Commercial Officer of Sirius Medical. “We are excited to bring these advanced solutions to even more markets, supporting healthcare providers and improving patient care on a larger scale.”
As a leading innovator in breast cancer diagnostics and surgical solutions, Mammotome is uniquely positioned to commercialize the Pintuition System. Backed by a deep understanding of the needs of breast care professionals and their patients, Mammotome will leverage its well-established sales network across Italy and Poland to ensure seamless access to Sirius Medical’s state-of-the-art technology.
“Our collaboration with Sirius Medical is built on mutual trust and a shared vision,” said Olaf Andrich, General Manager of EMEA and APAC for Mammotome. “Expanding distribution to these new countries is a natural next step that underscores our joint dedication to innovation and excellence in healthcare.”
This collaboration also enables healthcare providers and surgeons to benefit from Mammotome’s comprehensive portfolio of premium breast care products, including the Neoprobe Gamma Detection System and the HydroMARK Breast Biopsy Site Marker. Together, these technologies provide clinicians with a comprehensive suite of premium solutions designed to meet the evolving needs of breast surgery.